Table 1.
Ezogabine effects on CSD-induced activation of meningeal nociceptors
Increased activity
|
Decreased activity
|
|||||
---|---|---|---|---|---|---|
Experimental group | C-fibers | Aδ-fibers | % | C-fibers | Aδ-fibers | % |
Preemptive design (ezogabine given 2 min after CSD) | 4 | 2 | 40% | 4 | 5 | 60% |
Preemptive design – control I (vehicle given 2 min after CSD) | 1 | 2 | 50% | 3 | 0 | 50% |
Prophylactic design (ezogabine given 60 min before CSD) | 1 | 0 | 8% | 6 | 6 | 92% |
Drug effect – control II | 0 | 0 | 4 | 6 | ||
Spontaneous activity before CSD | 0.94±0.34 | 0.24±0.12 | 0.83±0.22 | 0.49±0.16 | ||
Spontaneous activity after CSD | 1.76±0.55 | 0.53±0.20 | 0.61±0.17 | 0.33±0.11 |